Critical Outcome Technologies Inc. (COTI) is a clinical-stage biopharmaceutical company. The Company is engaged in drug discovery and development. The Company uses machine learning to develop targeted therapies thereby managing the timeline and cost of getting new drug therapies to market. The Company's artificial intelligence platform, CHEMSAS, utilizes a series of predictive computer models to identify compounds with a high probability of being developed from disease specific drug discovery through chemical optimization and preclinical testing. The CHEMSAS platform technology is designed for small molecules, and as a drug candidate discovery engine can be applied to any disease target with information for the target of interest. The Company's initial focus is in advancing the treatment of cancer with the Company's lead compound, COTI-2, having a p53-dependent mechanism of action demonstrating selective and potent anti- cancer activity.